AB Science announces publication of three AB8939 scientific abstracts in the special ASH Annual Meeting issue of Blood

Paris, 09 December, 2019, 8.30am

AB Science announces publication of three AB8939 scientific abstracts in the special ASH Annual Meeting issue of Blood

AB Science SA (NYSE Euronext - FR0010557264 - AB) today announced that three scientific abstracts regarding its AB8939 preclinical development program were published in the special edition of the leading hematology journal Blood, prior to the start of the Annual Meeting of the American Society of Hematology (ASH) being held December 7-10^th in Orlando, Florida.

An overview of these AB8939 data (in vivo, ex vivo and in vitro), which are supportive for the treatment of acute myeloid leukemia (AML) were delivered by Professor Olivier Hermine (President of the Scientific Committee of AB Science and member of the Académie des Sciences in France) as part of the Chemical Biology and Experimental Therapeutics session.

“Taken together, these findings provide a compelling preclinical rationale for the development of AB8939 as a next-generation tubulin inhibitor for AML” commented Professor Olivier Hermine. “AB8939 seems particularly well-suited for treatment of relapsed/refractory AML and a first in human, Phase 1 trial of AB8939 in this indication is planned for next year”.

Ø  Details of the published abstracts
The journal citation and brief overview of each abstract is provided below. Full text from the abstracts is freely accessible online from the scientific journal Blood.

      §  In Vivo Assessment of the Next Generation Microtubule-Destabilizing Agent AB8939 in Patient-derived Xenograft Models of Acute Myeloid Leukemia
Goubard A, Humbert M, Mansfield C, Hermine O, Dubreuil P, et al.
Blood (2019) 134 (Supplement_1): 5142. DOI: https://doi.org/10.1182/blood-2019-127143
               
The therapeutic potential of AB8939 was investigated through a series of in vivo experiments using three patient-derived xenograft (PDX) mouse models and a cytarabine (Ara-C) resistant mouse model. Overall, these in vivo data provide compelling proof-of-concept for AB8939 as a treatment of AML. AB8939 administered alone or in combination with Ara-C was demonstrated to significantly increase survival and reduce tumor growth as compared with single agent Ara-C in relevant animal models of AML.